[go: up one dir, main page]

CA2334652A1 - Inhibiteurs de proteases - Google Patents

Inhibiteurs de proteases Download PDF

Info

Publication number
CA2334652A1
CA2334652A1 CA002334652A CA2334652A CA2334652A1 CA 2334652 A1 CA2334652 A1 CA 2334652A1 CA 002334652 A CA002334652 A CA 002334652A CA 2334652 A CA2334652 A CA 2334652A CA 2334652 A1 CA2334652 A1 CA 2334652A1
Authority
CA
Canada
Prior art keywords
leucyl
alkyl
pyrrolidin
group
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002334652A
Other languages
English (en)
Inventor
Robert W. Marquis, Jr.
Andrew D. Gribble
Jason Witherington
Ashley E. Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2334652A1 publication Critical patent/CA2334652A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Cette invention concerne des composés de formule (I) ou un sel pharmaceutiquement acceptable de ces derniers qui sont des inhibiteurs de cystéine protéases, particulièrement de la cathepsine K, et qui sont utilisés dans le traitement des maladies dans lesquelles la déperdition osseuse est un facteur.
CA002334652A 1998-06-12 1999-06-11 Inhibiteurs de proteases Abandoned CA2334652A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8905698P 1998-06-12 1998-06-12
US60/089,056 1998-06-12
PCT/US1999/013334 WO1999064399A1 (fr) 1998-06-12 1999-06-11 Inhibiteurs de proteases

Publications (1)

Publication Number Publication Date
CA2334652A1 true CA2334652A1 (fr) 1999-12-16

Family

ID=22215426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002334652A Abandoned CA2334652A1 (fr) 1998-06-12 1999-06-11 Inhibiteurs de proteases

Country Status (10)

Country Link
EP (1) EP1086083A4 (fr)
JP (1) JP2002517485A (fr)
AR (1) AR018652A1 (fr)
AU (1) AU4564499A (fr)
CA (1) CA2334652A1 (fr)
CO (1) CO5040090A1 (fr)
DZ (1) DZ2815A1 (fr)
MA (1) MA24877A1 (fr)
PE (1) PE20000725A1 (fr)
WO (1) WO1999064399A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1232154A4 (fr) 1999-11-10 2004-06-23 Smithkline Beecham Corp Inhibiteurs de protease
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
AU4344101A (en) 2000-03-21 2001-10-03 Smithkline Beecham Corp Protease inhibitors
WO2002080920A1 (fr) * 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-cetobenzoxazole comme inhibiteurs de la cysteine protease
EP1465862A1 (fr) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
WO2009087379A2 (fr) 2008-01-09 2009-07-16 Amura Therapeutics Limited Composés
CN117940420A (zh) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739204A4 (fr) * 1993-11-09 2000-03-15 Merck & Co Inc Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

Also Published As

Publication number Publication date
MA24877A1 (fr) 1999-12-31
EP1086083A1 (fr) 2001-03-28
CO5040090A1 (es) 2001-05-29
AR018652A1 (es) 2001-11-28
PE20000725A1 (es) 2000-09-28
DZ2815A1 (fr) 2003-12-01
WO1999064399A1 (fr) 1999-12-16
AU4564499A (en) 1999-12-30
EP1086083A4 (fr) 2001-09-26
JP2002517485A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
CA2262668C (fr) Inhibiteurs de la cathepsine k
US6369077B1 (en) Protease inhibitors
WO1998008802A1 (fr) Inhibiteurs de cysteine protease
NZ337889A (en) Cysteine Protease inhibitors of the Papain superfamily comprising cathepsin K protease inhibitors
CA2334652A1 (fr) Inhibiteurs de proteases
US20020128476A1 (en) Inhibitors of cysteine protease
EP1235577A2 (fr) Inhibiteurs de protease
US6596715B1 (en) Protease inhibitors
WO2000029408A1 (fr) Inhibiteurs de morpholino-ethoxybenzofuran protease
US6534498B1 (en) Protease inhibitors
EP1231921A1 (fr) Inhibiteurs de proteases
EP1229915A1 (fr) Inhibiteurs de protease
WO2000058296A1 (fr) Inhibiteurs de protease
WO2001034155A1 (fr) Inhibiteurs de protease
US20020082426A1 (en) Protease inhibitors
US6583137B1 (en) Protease inhibitors
WO2001034157A1 (fr) Inhibiteurs de protease
CA2285601A1 (fr) Inhibiteurs de proteases
EP1384713B1 (fr) Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
US20020165222A1 (en) Protease inhibitors
MXPA99010254A (en) Protease inhibitors

Legal Events

Date Code Title Description
FZDE Dead